Skip to content
Back to Guavy Wire
Stocks

Scotiabank Analyst Maintains Buy Rating for Amgen with Target Price $450

Instruments
AMGN
Share

Scotiabank analyst Louise Chen has reaffirmed her Buy rating for Amgen (AMGN.US), maintaining a target price of $450.

According to TipRanks data, Chen's success rate over the past year is 53.2%, with an average return of 7.0%.

This means that out of all the ratings provided by Chen in the past year, 53.2% have been successful, resulting in a positive return for the TipRanks' virtual portfolio.

More on Stocks

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

© 2026 Guavy Inc